- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00081744
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
February 7, 2013 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
A Multicenter, Double-Blind, Randomized Comparison Study Of the Efficacy and Safety of Tigecycline to Imipenem/ Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects
Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
850
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects, ≥ 8 years of age and a weight of ≥ 35 kilograms
- Subjects with selected culture-positive infections caused by a multiple antibiotic-resistant pathogen presumed to be susceptible to tigecycline
- Subjects who have failed or are intolerant of other available appropriate antibiotic therapies or whose pathogens are resistant to other available antibiotics
Exclusion Criteria:
- Subjects who are moribund with an expected survival of less than 2 weeks.
- Subjects who have been designated as "Do Not Resuscitate", unless it is anticipated within a reasonable degree of medical certainty that they can achieve benefit from potentially curative antibiotic therapy
- Known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds related to this class of antibacterial agents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E; 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis. 2005 Oct 19;5:88. doi: 10.1186/1471-2334-5-88.
- Fomin P, Koalov S, Cooper A, Babinchak T, Dartois N, De Vane N, Castaing N, Tellado J; 301 And 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. J Chemother. 2008 Oct;20 Suppl 1:12-9. doi: 10.1179/joc.2008.20.Supplement-1.12.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2002
Primary Completion (Actual)
August 1, 2004
Study Completion (Actual)
August 1, 2004
Study Registration Dates
First Submitted
April 19, 2004
First Submitted That Met QC Criteria
April 20, 2004
First Posted (Estimate)
April 21, 2004
Study Record Updates
Last Update Posted (Estimate)
February 8, 2013
Last Update Submitted That Met QC Criteria
February 7, 2013
Last Verified
February 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Bacterial Infections and Mycoses
- Iatrogenic Disease
- Infections
- Communicable Diseases
- Intraabdominal Infections
- Bacterial Infections
- Cross Infection
- Gram-Positive Bacterial Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Tigecycline
Other Study ID Numbers
- 3074A1-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gram-Positive Bacterial Infections
-
Ministry of Health, RwandaUnknownDisease Due to Gram-positive BacteriaRwanda
-
Melinta Therapeutics, LLCRecruitingGram Positive Bacterial InfectionsUnited States
-
Cubist Pharmaceuticals LLCCompletedGram-positive Bacterial InfectionsUnited States
-
Imperial College LondonHammersmith Hospitals NHS TrustCompletedStaphylococcal Infections | Gram-positive Bacterial InfectionsUnited Kingdom
-
Cubist Pharmaceuticals LLCCompleted
-
NovartisNovartis VaccinesCompletedBacterial Infection | Streptococcal Infection | Gram-positive Bacterial InfectionBelgium, Canada
-
Cumberland PharmaceuticalsTerminatedGram-Positive Bacterial InfectionsUnited States
-
Universitaire Ziekenhuizen KU LeuvenCompletedGram-Positive Bacterial InfectionsBelgium
-
PfizerAventis PharmaceuticalsTerminatedGram-Positive Bacterial InfectionsUnited States
-
University of ZurichUnknownGram-Positive Bacterial InfectionsSwitzerland
Clinical Trials on Tigecycline
-
PfizerCompletedIntra-Abdominal Infections | Skin Disease, Infectious
-
Phramongkutklao College of Medicine and HospitalSilpakorn UniversityRecruiting
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedStudy Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative OrganismsGram-Negative Bacterial Infections
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAbdominal AbscessTaiwan
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedCommunity-Acquired InfectionsJapan
-
PfizerCompletedComplicated Skin and Skin Structure Infections | Complicated Intra-abdominal InfectionsPhilippines
-
PfizerCompletedComplicated Skin and Skin Structure Infections | Complicated Intra-abdominal Infections | Community-Acquired Bacterial PneumoniaKorea, Republic of
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedLiver Cirrhosis, BiliaryUnited States, Puerto Rico